ArticleWorld journal of surgical oncology2025
Nomogram for survival prediction in metastatic differentiated thyroid cancer and survival comparison between systemic chemotherapy and local radiotherapy in high-risk patients.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistant metastases are the leading cause of death for patients with differentiated thyroid cancer (DTC), and surgery and radioactive iodine (RAI) therapy are effective treatments for them. However, there remains a large proportion of patients with poor prognoses, and there exists no consensus on whether systemic chemotherapy or beam radiation should be administrated to improve their prognoses.
methodThe clinicopathology information of patients with metastatic DTC (mDTC) was retrospectively collected and analyzed. A nomogram was created to predict their prognosis and divided patients into high- and low-risk groups, and the external validation was performed.
resultsThe Cox regression showed that sex, age, metastatic sites, surgery, and radiotherapy were independent influencing factors affecting OS. Fine-gray competing risk analysis showed that age, T-stage, N-stage, metastatic sites, and radiotherapy were independent risk factors for TCSD. The nomogram we constructed proved to be effective and robust with high efficiency, with C-indexes of 0.785 (95% CI = 0.752-0.813) and 0.794 (95%CI = 0.766-0.831) on the train and test sets, respectively. mDTC patients were further classified into high- and low-risk groups based on the prediction of nomogram, those in the high-risk group had significantly worse OS and higher TCSD than those in the low-risk group (P < 0.001), and chemotherapy significantly improved OS and reduced TCSD for patients in the high-risk group, whereas local beam radiation did not provide any survival benefit. In the external validation dataset, the 1-, 3-, and 5-year AUC values of the model ranged from 0.833 to 0.873, which further proved the efficiency of our model.
conclusionThis study developed an accurate prognostic model for patients with mDTC, which may be applicable in future clinical practice for prognosis and death prediction. For high-risk patients, as predicted by nomogram, systemic chemotherapy was the recommended therapy option for them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.